Is BRNS or INO more profitable?

Barinthus Biotherapeutics' return on equity of -59.15% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Barinthus Biotherapeutics N/A -59.15% -43.80% Inovio Pharmaceuticals N/A -669.94% -73.97%

Which has better valuation and earnings, OKUR or BRNS?

OnKure Therapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OnKure Therapeutics N/A N/A -$59.52M -$3.50 N/A Barinthus Biotherapeutics N/A N/A -$66.43M -$1.03 N/A

Is OKUR or BRNS more profitable?

OnKure Therapeutics' return on equity of -49.01% beat Barinthus Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets OnKure Therapeutics N/A -49.01% -45.77% Barinthus Biotherapeutics N/A -59.15% -43.80%

Which has better earnings & valuation, BRNS or PMN?

Promis Neurosciences is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Barinthus Biotherapeutics N/A N/A -$66.43M -$1.03 N/A Promis Neurosciences N/A N/A -$39.72M -$8.54 N/A

Is BRNS or PMN more profitable?

Barinthus Biotherapeutics' return on equity of -59.15% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Barinthus Biotherapeutics N/A -59.15% -43.80% Promis Neurosciences N/A -143.09% -109.15%

Is RANI or BRNS more profitable?

Barinthus Biotherapeutics' return on equity of -59.15% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rani Therapeutics N/A -104.60% -65.17% Barinthus Biotherapeutics N/A -59.15% -43.80%

Barinthus Biotherapeutics (BRNS) Competitors

$0.74 0.00 (0.00%)

As of 09/18/2026

Compare

BRNS vs. CBUS, INO, OKUR, PMN, and RANI

Should you buy Barinthus Biotherapeutics stock or one of its competitors? Barinthus Biotherapeutics's main competitors and comparable companies include Cibus (CBUS), Inovio Pharmaceuticals (INO), OnKure Therapeutics (OKUR), Promis Neurosciences (PMN), and Rani Therapeutics (RANI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Barinthus Biotherapeutics compare to Cibus?

Cibus (NASDAQ:CBUS) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

Barinthus Biotherapeutics has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Barinthus Biotherapeutics' return on equity of -59.15% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cibus	-2,258.89%	-287.03%	-27.99%
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%

Barinthus Biotherapeutics has lower revenue, but higher earnings than Cibus. Cibus is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cibus	$3.64M	33.81	-$127.08M	-$1.65	N/A
Barinthus Biotherapeutics	N/A	N/A	-$66.43M	-$1.03	N/A

Cibus has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.37, meaning that its stock price is 137% less volatile than the broader market.

Cibus presently has a consensus price target of $9.00, suggesting a potential upside of 459.01%. Barinthus Biotherapeutics has a consensus price target of $4.00, suggesting a potential upside of 440.54%. Given Cibus' higher probable upside, equities research analysts clearly believe Cibus is more favorable than Barinthus Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Barinthus Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

33.8% of Cibus shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 29.9% of Cibus shares are held by insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Cibus had 1 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 1 mentions for Cibus and 0 mentions for Barinthus Biotherapeutics. Cibus' average media sentiment score of 0.36 beat Barinthus Biotherapeutics' score of 0.00 indicating that Cibus is being referred to more favorably in the media.

Company	Overall Sentiment
Cibus	Neutral
Barinthus Biotherapeutics	Neutral

Summary

Cibus beats Barinthus Biotherapeutics on 8 of the 12 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Inovio Pharmaceuticals?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

In the previous week, Inovio Pharmaceuticals had 3 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 3 mentions for Inovio Pharmaceuticals and 0 mentions for Barinthus Biotherapeutics. Inovio Pharmaceuticals' average media sentiment score of 0.64 beat Barinthus Biotherapeutics' score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Barinthus Biotherapeutics	Neutral
Inovio Pharmaceuticals	Positive

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 8.5% of Barinthus Biotherapeutics shares are owned by company insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Barinthus Biotherapeutics has a beta of -0.37, meaning that its share price is 137% less volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.63, meaning that its share price is 63% more volatile than the broader market.

Barinthus Biotherapeutics' return on equity of -59.15% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%

Barinthus Biotherapeutics presently has a consensus target price of $4.00, indicating a potential upside of 440.54%. Inovio Pharmaceuticals has a consensus target price of $3.17, indicating a potential upside of 155.38%. Given Barinthus Biotherapeutics' higher probable upside, research analysts plainly believe Barinthus Biotherapeutics is more favorable than Inovio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Barinthus Biotherapeutics has higher earnings, but lower revenue than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	N/A	N/A	-$66.43M	-$1.03	N/A
Inovio Pharmaceuticals	$60K	2,136.93	-$84.95M	-$0.91	N/A

Summary

Inovio Pharmaceuticals beats Barinthus Biotherapeutics on 9 of the 15 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to OnKure Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

OnKure Therapeutics' return on equity of -49.01% beat Barinthus Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-49.01%	-45.77%
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%

OnKure Therapeutics has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.37, suggesting that its share price is 137% less volatile than the broader market.

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. 2.2% of OnKure Therapeutics shares are owned by insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

OnKure Therapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A
Barinthus Biotherapeutics	N/A	N/A	-$66.43M	-$1.03	N/A

In the previous week, OnKure Therapeutics' average media sentiment score of 0.00 equaled Barinthus Biotherapeutics'average media sentiment score.

Company	Overall Sentiment
OnKure Therapeutics	Neutral
Barinthus Biotherapeutics	Neutral

OnKure Therapeutics currently has a consensus price target of $17.50, indicating a potential upside of 493.22%. Barinthus Biotherapeutics has a consensus price target of $4.00, indicating a potential upside of 440.54%. Given OnKure Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe OnKure Therapeutics is more favorable than Barinthus Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Barinthus Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

OnKure Therapeutics beats Barinthus Biotherapeutics on 7 of the 10 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Promis Neurosciences?

Barinthus Biotherapeutics (NASDAQ:BRNS) and Promis Neurosciences (NASDAQ:PMN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

In the previous week, Barinthus Biotherapeutics' average media sentiment score of 0.00 equaled Promis Neurosciences'average media sentiment score.

Company	Overall Sentiment
Barinthus Biotherapeutics	Neutral
Promis Neurosciences	Neutral

Barinthus Biotherapeutics has a beta of -0.37, meaning that its stock price is 137% less volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.24, meaning that its stock price is 124% less volatile than the broader market.

Promis Neurosciences is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	N/A	N/A	-$66.43M	-$1.03	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$8.54	N/A

25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are held by institutional investors. 8.5% of Barinthus Biotherapeutics shares are held by insiders. Comparatively, 1.5% of Promis Neurosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Barinthus Biotherapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 440.54%. Promis Neurosciences has a consensus target price of $34.00, suggesting a potential upside of 142.68%. Given Barinthus Biotherapeutics' higher possible upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Barinthus Biotherapeutics' return on equity of -59.15% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%
Promis Neurosciences	N/A	-143.09%	-109.15%

Summary

Promis Neurosciences beats Barinthus Biotherapeutics on 6 of the 11 factors compared between the two stocks.

How does Barinthus Biotherapeutics compare to Rani Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability.

Rani Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.37, indicating that its stock price is 137% less volatile than the broader market.

Rani Therapeutics presently has a consensus price target of $8.75, suggesting a potential upside of 915.08%. Barinthus Biotherapeutics has a consensus price target of $4.00, suggesting a potential upside of 440.54%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Rani Therapeutics is more favorable than Barinthus Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Barinthus Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Barinthus Biotherapeutics' return on equity of -59.15% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-104.60%	-65.17%
Barinthus Biotherapeutics	N/A	-59.15%	-43.80%

30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. 26.7% of Rani Therapeutics shares are held by insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Rani Therapeutics' average media sentiment score of 0.00 equaled Barinthus Biotherapeutics'average media sentiment score.

Company	Overall Sentiment
Rani Therapeutics	Neutral
Barinthus Biotherapeutics	Neutral

Rani Therapeutics has higher revenue and earnings than Barinthus Biotherapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	73.72	-$29.67M	-$0.27	N/A
Barinthus Biotherapeutics	N/A	N/A	-$66.43M	-$1.03	N/A

Summary

Rani Therapeutics beats Barinthus Biotherapeutics on 10 of the 13 factors compared between the two stocks.

Get Barinthus Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BRNS vs. The Competition

Export

Metric	Barinthus Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$30.23M	$3.89B	$7.25B	$12.95B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	-0.72	8.10	210.29	20.60
Price / Sales	N/A	1,456.59	656.37	93.45
Price / Cash	N/A	41.62	28.13	34.74
Price / Book	0.41	15.47	10.50	6.32
Net Income	-$66.43M	-$22.90M	$3.49B	$358.20M
7 Day Performance	N/A	-1.21%	0.59%	1.12%
1 Month Performance	20.86%	-3.29%	-1.74%	-2.39%
1 Year Performance	-32.42%	37.74%	18.13%	5.35%

Barinthus Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BRNS Barinthus Biotherapeutics	1.7553 of 5 stars	$0.74 flat	$4.00 +440.5%	N/A	$30.23M	N/A	N/A	107
CBUS Cibus	1.5392 of 5 stars	$1.51 -4.4%	$9.00 +496.0%	+13.4%	$120.76M	$3.64M	N/A	118	News Coverage Analyst Downgrade
INO Inovio Pharmaceuticals	3.0742 of 5 stars	$1.15 -0.9%	$3.17 +175.4%	-46.1%	$119.94M	$60K	N/A	112	News Coverage
OKUR OnKure Therapeutics	2.3531 of 5 stars	$2.88 -1.7%	$17.50 +507.6%	+14.8%	$118.36M	N/A	N/A	45	Positive News
PMN Promis Neurosciences	3.137 of 5 stars	$12.88 -0.1%	$34.00 +164.0%	+26.9%	$115.59M	N/A	N/A	11

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BRNS) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Barinthus Biotherapeutics (BRNS) Competitors

BRNS vs. CBUS, INO, OKUR, PMN, and RANI

How does Barinthus Biotherapeutics compare to Cibus?

Summary

How does Barinthus Biotherapeutics compare to Inovio Pharmaceuticals?

Summary

How does Barinthus Biotherapeutics compare to OnKure Therapeutics?

Summary

How does Barinthus Biotherapeutics compare to Promis Neurosciences?

Summary

How does Barinthus Biotherapeutics compare to Rani Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS vs. The Competition

Barinthus Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Barinthus Biotherapeutics (BRNS) Competitors

BRNS vs. CBUS, INO, OKUR, PMN, and RANI

How does Barinthus Biotherapeutics compare to Cibus?

Is CBUS or BRNS more profitable?

Which has stronger earnings & valuation, CBUS or BRNS?

Which has more risk & volatility, CBUS or BRNS?

Do analysts prefer CBUS or BRNS?

Do insiders & institutionals hold more shares of CBUS or BRNS?

Does the media prefer CBUS or BRNS?

Summary

How does Barinthus Biotherapeutics compare to Inovio Pharmaceuticals?

Does the media favor BRNS or INO?

Do institutionals & insiders believe in BRNS or INO?

Which has more risk and volatility, BRNS or INO?

Is BRNS or INO more profitable?

Do analysts recommend BRNS or INO?

Which has better earnings & valuation, BRNS or INO?

Summary

How does Barinthus Biotherapeutics compare to OnKure Therapeutics?

Is OKUR or BRNS more profitable?

Which has more risk & volatility, OKUR or BRNS?

Do insiders and institutionals have more ownership in OKUR or BRNS?

Which has better valuation and earnings, OKUR or BRNS?

Does the media prefer OKUR or BRNS?

Do analysts recommend OKUR or BRNS?

Summary

How does Barinthus Biotherapeutics compare to Promis Neurosciences?

Does the media favor BRNS or PMN?

Which has more volatility & risk, BRNS or PMN?

Which has better earnings & valuation, BRNS or PMN?

Do insiders & institutionals believe in BRNS or PMN?

Do analysts prefer BRNS or PMN?

Is BRNS or PMN more profitable?

Summary

How does Barinthus Biotherapeutics compare to Rani Therapeutics?

Which has more risk and volatility, RANI or BRNS?

Do analysts rate RANI or BRNS?

Is RANI or BRNS more profitable?

Do insiders and institutionals have more ownership in RANI or BRNS?

Does the media prefer RANI or BRNS?

Which has stronger earnings and valuation, RANI or BRNS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRNS vs. The Competition

Barinthus Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools